

Pedro Farinha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2090823/publications.pdf>

Version: 2024-02-01

107
papers

11,587
citations

71061

41
h-index

39638

94
g-index

110
all docs

110
docs citations

110
times ranked

11590
citing authors

#	ARTICLE	IF	CITATIONS
1	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004, 103, 275-282.	0.6	3,574
2	Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 362, 875-885.	13.9	1,141
3	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. <i>Blood</i> , 2009, 114, 3533-3537.	0.6	566
4	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. <i>Nature</i> , 2011, 471, 377-381.	13.7	551
5	Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). <i>Blood</i> , 2005, 106, 2169-2174.	0.6	427
6	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2848-2856.	0.8	334
7	Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- κ B pathways in subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2008, 111, 3701-3713.	0.6	315
8	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 190-201.	0.8	257
9	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. <i>Cancer Discovery</i> , 2019, 9, 546-563.	7.7	213
10	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. <i>Blood</i> , 2009, 113, 5536-5548.	0.6	205
11	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. <i>PLoS Medicine</i> , 2016, 13, e1002197.	3.9	185
12	<i>Helicobacter pylori</i> and MALT Lymphoma. <i>Gastroenterology</i> , 2005, 128, 1579-1605.	0.6	184
13	Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 692-700.	0.8	176
14	The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. <i>Blood</i> , 2010, 115, 289-295.	0.6	173
15	Molecular Pathogenesis of Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 6370-6378.	0.8	172
16	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , 2018, 131, 2060-2064.	0.6	167
17	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 447-454.	0.8	159
18	Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 406-421.	7.7	155

#	ARTICLE	IF	CITATIONS
19	Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. <i>Blood</i> , 2010, 116, 418-427.	0.6	152
20	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. <i>Blood</i> , 2016, 127, 2182-2188.	0.6	145
21	Prognostic Factors in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2902-2913.	0.8	136
22	Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , 2005, 11, 1065-72.	3.2	130
23	Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 120, 3530-3540.	0.6	122
24	Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. <i>Cell Reports</i> , 2015, 13, 1418-1431.	2.9	112
25	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. <i>Blood</i> , 2017, 129, 2760-2770.	0.6	112
26	Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. <i>Nature Communications</i> , 2018, 9, 4001.	5.8	102
27	The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. <i>Clinical Cancer Research</i> , 2015, 21, 3428-3435.	3.2	101
28	Cell of origin of transformed follicular lymphoma. <i>Blood</i> , 2015, 126, 2118-2127.	0.6	91
29	Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. <i>Blood</i> , 2019, 134, 761-764.	0.6	77
30	High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. <i>Blood Advances</i> , 2018, 2, 2755-2765.	2.5	74
31	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. <i>Blood</i> , 2016, 127, 2203-2213.	0.6	68
32	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. <i>Haematologica</i> , 2010, 95, 96-101.	1.7	63
33	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. <i>Cell</i> , 2020, 182, 297-316.e27.	13.5	63
34	Mutational landscape of gray zone lymphoma. <i>Blood</i> , 2021, 137, 1765-1776.	0.6	60
35	Hypoxia-Inducible Factor-1 \pm Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2010, 28, 1017-1024.	0.8	57
36	Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2021, 137, 929-938.	0.6	57

#	ARTICLE	IF	CITATIONS
37	Identification of high-risk <i>DUSP22</i> rearranged <i>ALK</i> -negative anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e28-e31.	1.2	56
38	Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma. <i>Cancer Cell</i> , 2020, 37, 674-689.e12.	7.7	55
39	Macrophages predict treatment outcome in Hodgkin's lymphoma. <i>Haematologica</i> , 2011, 96, 186-189.	1.7	50
40	Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. <i>Blood</i> , 2020, 136, 2803-2811.	0.6	46
41	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. <i>Nature Medicine</i> , 2020, 26, 577-588.	15.2	46
42	Vascularization predicts overall survival and risk of transformation in follicular lymphoma. <i>Haematologica</i> , 2010, 95, 2157-2160.	1.7	44
43	HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. <i>Leukemia and Lymphoma</i> , 2007, 48, 542-546.	0.6	43
44	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , 2019, 3, 2013-2021.	2.5	40
45	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). <i>British Journal of Haematology</i> , 2010, 148, 235-244.	1.2	38
46	MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2903-2911.	0.8	37
47	Gene expression profiling of gray zone lymphoma. <i>Blood Advances</i> , 2020, 4, 2523-2535.	2.5	32
48	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. <i>Blood</i> , 2018, 131, 226-235.	0.6	31
49	Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas. <i>Cancer Research</i> , 2008, 68, 3361-3369.	0.4	30
50	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. <i>Haematologica</i> , 2010, 95, 2056-2062.	1.7	28
51	Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	26
52	High Frequency of MALT Lymphoma in a Series of 14 Cases of Primary Breast Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2002, 10, 115-120.	0.6	20
53	Characterization of DLBCL with a PMBL gene expression signature. <i>Blood</i> , 2021, 138, 136-148.	0.6	19
54	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. <i>Blood</i> , 2021, 137, 2196-2208.	0.6	18

#	ARTICLE	IF	CITATIONS
55	Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). <i>Blood</i> , 2019, 134, 401-401.	0.6	18
56	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. <i>Haematologica</i> , 2018, 103, e590-e593.	1.7	16
57	Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. <i>Lupus Science and Medicine</i> , 2019, 6, e000324.	1.1	16
58	Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R.. <i>Blood</i> , 2006, 108, 812-812.	0.6	15
59	Title is missing!. <i>Applied Immunohistochemistry & Molecular Morphology</i> , 2002, 10, 115-120.	2.0	12
60	Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 620-629.	1.1	12
61	Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis. <i>Immunity</i> , 2021, 54, 1807-1824.e14.	6.6	12
62	Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations.. <i>Blood</i> , 2009, 114, 268-268.	0.6	12
63	Blastic plasmacytoid dendritic cell neoplasm. <i>Anais Brasileiros De Dermatologia</i> , 2013, 88, 158-161.	0.5	11
64	Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204533-bcr2014204533.	0.2	10
65	Mechanisms of Bcl-2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2004, 104, 26-26.	0.6	9
66	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 267-278.e10.	0.2	8
67	The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 495-495.	0.6	8
68	Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology. <i>Blood</i> , 2021, 138, 2499-2499.	0.6	8
69	Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. <i>Blood Advances</i> , 2021, 5, 2945-2957.	2.5	7
70	Addition of Rituximab (R) to CHOP Improves Survival in the Non-GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2006, 108, 816-816.	0.6	6
71	Transformation of a Cutaneous Follicle Center Lymphoma to a Diffuse Large B-Cell Lymphoma—An Unusual Presentation. <i>Case Reports in Medicine</i> , 2010, 2010, 1-5.	0.3	5
72	Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 113-117.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Predicting Survival in Follicular Lymphoma Using Tissue Microarrays. <i>Methods in Molecular Biology</i> , 2007, 377, 255-268.	0.4	5
74	The Tumor Microenvironment Measured by Flow Cytometry Predicts Overall Survival (OS) and Transformation Risk (TR) in Follicular Lymphoma.. <i>Blood</i> , 2006, 108, 2406-2406.	0.6	5
75	Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 703-703.	0.6	5
76	Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 2919-2919.	0.6	5
77	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. <i>Blood Advances</i> , 2021, 5, 3647-3655.	2.5	4
78	Primary cutaneous follicle center lymphoma of the medial canthus of the eye in an 11-year old. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29630.	0.8	4
79	Hepatosplenic T-cell lymphoma: a rare cause of hepatosplenomegaly. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013009423-bcr2013009423.	0.2	3
80	The Architectural Pattern of FOXP3+ T Cells Predicts Risk of Transformation in Patients with Follicular Lymphoma (FL).. <i>Blood</i> , 2007, 110, 358-358.	0.6	3
81	HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy.. <i>Blood</i> , 2009, 114, 133-133.	0.6	3
82	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1560-1560.	0.6	2
83	Single Cell Transcriptome Analysis Reveals Disease-Defining T Cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 547-547.	0.6	2
84	TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP. <i>Blood</i> , 2019, 134, 3964-3964.	0.6	2
85	Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008, 112, 479-479.	0.6	2
86	Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2009, 114, 3944-3944.	0.6	2
87	Combined FOXP3+ and PD1+ T Cell Density and Architectural Patterns Predict Overall Survival and Risk of Transformation in Uniformly Treated Patients with Follicular Lymphoma. <i>Blood</i> , 2008, 112, 2815-2815.	0.6	2
88	The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL. <i>Blood</i> , 2018, 132, 921-921.	0.6	1
89	Lymphoma-Associated Macrophage (LAM) Content Is an Independent Predictor of Survival in Patients with Follicular Lymphoma (FL).. <i>Blood</i> , 2004, 104, 3259-3259.	0.6	1
90	The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.. <i>Blood</i> , 2009, 114, 2923-2923.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry. <i>Blood</i> , 2014, 124, 1624-1624.	0.6	1
92	Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype. <i>Blood</i> , 2015, 126, 109-109.	0.6	1
93	PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1509-1509.	0.6	1
94	The impact of surveillance imaging after curative-intent radiotherapy for limited-stage follicular lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 802-805.	1.2	1
95	PD2-2-7: Two wrongs make a right: the use of whole genome amplification for pair-wise genome-wide copy number analysis of limited patient material. <i>Journal of Thoracic Oncology</i> , 2007, 2, S442-S443.	0.5	0
96	Fever and generalised lymphadenopathy in an HIV-positive patient: a diagnostic challenge. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220740.	0.2	0
97	Diffuse large B-cell lymphoma versus Burkitt lymphoma with discordant diagnostic cytogenetics: Morphology trumps. <i>EJHaem</i> , 0, , .	0.4	0
98	HLA-DR Protein Status Predicts Survival in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with the MACOP-B Chemotherapy Regimen.. <i>Blood</i> , 2004, 104, 3273-3273.	0.6	0
99	Vascularization Predicts Overall Survival (OS) & Risk of Transformation (RT) in Uniformly Treated Patients with Follicular Lymphoma (FL).. <i>Blood</i> , 2007, 110, 184-184.	0.6	0
100	Genetic Alterations of G13 Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 111-111.	0.6	0
101	Divergent Modes of Tumor Evolution Underlie Histological Transformation and Early Progression of Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1091-1091.	0.6	0
102	Intravascular large B-cell lymphoma presenting with acute encephalopathy. <i>Blood</i> , 2020, 135, 1916-1916.	0.6	0
103	Constrained FL: A Genetically Distinct Subgroup of Follicular Lymphoma with Low Rates of Somatic Hypermutation and a Reduced Propensity for Histologic Transformation. <i>Blood</i> , 2021, 138, 807-807.	0.6	0
104	Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification. <i>Blood</i> , 2021, 138, 719-719.	0.6	0
105	Single Cell Profiling Reveals Unique CXCL13 Positive T Cell Subsets in the Tumor Microenvironment of Lymphocyte Rich Classic Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 32-33.	0.6	0
106	ALK+ hyaline-vascular Castleman disease: A new kid on the block. <i>Histopathology</i> , 2022, , .	1.6	0
107	Predicting Survival in Follicular Lymphoma Using Tissue Microarrays. , 0, , 255-268.		0